|
KMID : 0370220240680010010
|
|
Yakhak Hoeji
2024 Volume.68 No. 1 p.10 ~ p.25
|
|
|
Cost-utility Analysis Methods of Androgen Receptor Targeted Agents for Metastatic Hormone-Sensitive Prostate Cancer: A Systematic Review
|
|
Cho Yoon
Youm Jae-Yoon
Kang Hye-Young
Lee Han-Kil
|
|
|
Abstract
|
|
|
|
As the clinical effectiveness of androgen receptor targeting agents (ARTAs) has been proven, countriesworldwide recommend ARTAs treatment to delay the progression of metastatic hormone-sensitive prostate cancer(mHSPC). This study aimed to summarize the methods and data resources by systematically reviewing the cost-utilityanalysis (CUA) studies of ARTAs in patients with mHSPC. PubMed, Embase and Cochrane Library databases wereutilized for literature searches, and the relevant studies were selected with pre-defined inclusion/exclusion criteria accordingto the PRISMA guideline. The Consolidated Health Economic Evaluation Reporting Standards checklist was used to assessselected studies’ risk-of-bias. Of the 362 publications identified initially, ten eligible studies from six countries wereincluded. All studies were trial-based CUA studies. Ten studies were selected which included eighteen CUAs (eightabiraterone acetate, four apalutamide, and six enzalutamide as interventions, and the comparator was ADT with ARTAs ordocetaxel, or ADT alone). Eight studies used Markov models with key health states (mHSPC, mCRPC, death), while therest were structured as partitioned survival analysis model and descriptive-analytical model, respectively. All the transitionprobabilities were derived from the pivotal clinical studies. Utility values were calculated by referring to studies thatdirectly measured utility values such as randomized controlled trials or previous literature on economic evaluations orutility, while costs were estimated from real-world data from each country. The reporting quality of studies is valid from79.2% to 100% (median 95.8%). The results of this study can serve as valid input values for elaborating CUA studies ofARTAs in the future.
|
|
|
KEYWORD
|
|
|
Metastatic hormone sensitive prostate cancer, Androgen receptor targeted agents, Systematic review, Cost-utility analysis
|
|
|
FullTexts / Linksout information
|
|
|
|
|
|
Listed journal information
|
|
|
|
|